Aurora Spine (TSXV:ASG) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

ASG Aktienübersicht

Die Aurora Spine Corporation ist über ihre Tochtergesellschaft Aurora Spine, Inc. in der Entwicklung und dem Vertrieb von minimal-invasiven Systemen und Geräten zur Fusion der Wirbelsäule in Kanada tätig.

Über das Unternehmen

ASG fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Belohnungen

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Die Erträge sind in den letzten 5 Jahren um 22.9% pro Jahr zurückgegangen

Die Aktionäre wurden im vergangenen Jahr verwässert

Signifikante Insiderverkäufe in den letzten 3 Monaten

+ 2 mehr Risiken

Aurora Spine Corporation Wettbewerber

MedX Health

TSXV:MDX

CA$23.6m

Theralase Technologies

TSXV:TLT

CA$45.5m

Nanalysis Scientific

TSXV:NSCI

CA$51.4m

Scryb

CNSX:SCYB

CA$8.7m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Aurora Spine
Historical stock prices
Current Share Price	CA$0.26
52 Week High	CA$0.47
52 Week Low	CA$0.22
Beta	0.72
1 Month Change	-8.77%
3 Month Change	-23.53%
1 Year Change	-10.34%
3 Year Change	-63.89%
5 Year Change	-39.53%
Change since IPO	-80.74%

Aktuelle Nachrichten und Updates

Is Aurora Spine (CVE:ASG) A Risky Investment?

May 29

Recent updates

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aug 11

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

May 01

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Dec 22

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aug 23

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

May 04

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Dec 23

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Jun 11

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

Feb 26

Is Aurora Spine (CVE:ASG) A Risky Investment?

Nov 19

Aktionärsrenditen

	ASG	CA Medical Equipment	CA Markt
7D	0%	6.8%	-1.4%
1Y	-10.3%	-34.5%	10.8%

Rendite im Vergleich zur Industrie: ASG übertraf die Branche Canadian Medical Equipment, die im vergangenen Jahr eine Rendite von -27.7 erzielte.

Rendite vs. Markt: ASG hinter dem Markt Canadian zurück, der im vergangenen Jahr eine Rendite von 12.4 erzielte.

Preisvolatilität

Is ASG's price volatile compared to industry and market?
ASG volatility
ASG Average Weekly Movement	15.1%
Medical Equipment Industry Average Movement	9.4%
Market Average Movement	8.5%
10% most volatile stocks in CA Market	17.0%
10% least volatile stocks in CA Market	3.0%

Stabiler Aktienkurs: ASGDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: ASGDie wöchentliche Volatilität (15%) war im letzten Jahr stabil, liegt aber immer noch höher als bei 75 % der Canadian Aktien.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2013	n/a	Trent Northcutt	www.aurora-spine.com

Die Aurora Spine Corporation ist über ihre Tochtergesellschaft Aurora Spine, Inc. in der Entwicklung und dem Vertrieb von minimalinvasiven interspinalen Fusionssystemen und -geräten in Kanada tätig. Das Unternehmen bietet interspinöse Lendenwirbelfusionssysteme wie ZIP, ZIP ULTRA, ZIP LP und ZIP-51 für Patienten mit degenerativen Bandscheibenerkrankungen sowie Ti-Coated Polyetheretherketon Interbody Cages an, die für Abstand und Stabilität zwischen den Wirbeln sorgen, während der Knochen wächst, um den Fusionsprozess abzuschließen. Darüber hinaus bietet das Unternehmen steril verpackte, mit Titanplasmaspray beschichtete Wirbelsäuleninfusionsimplantate für das Knochenwachstum sowie Interbody-Produkte wie EOS, VOX, Echo, Echo SD und EchoXL für den lumbalen Bereich der Wirbelsäule und Discovery für zervikale Verfahren.

Aurora Spine Corporation's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Aurora Spine im Vergleich zum Marktanteil des Unternehmens?
ASG grundlegende Statistiken
Marktanteil	CA$20.01m
Gewinn(TTM)	-CA$1.77m
Umsatz(TTM)	CA$21.42m

0.9x

Kurs-Umsatz-Verhältnis

-11.3x

Kurs-Gewinn-Verhältnis

Ist ASG zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ASG Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$15.58m
Kosten der Einnahmen	US$6.41m
Bruttogewinn	US$9.17m
Sonstige Ausgaben	US$10.45m
Umsatz	-US$1.28m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.017
Bruttomarge	58.86%
Nettogewinnspanne	-8.25%
Schulden/Eigenkapital-Verhältnis	51.2%

Wie hat sich ASG auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ASG Aktienübersicht

Belohnungen

Risikoanalyse

Aurora Spine Corporation Wettbewerber

TSXV:MDX

CA$23.6m

TSXV:TLT

CA$45.5m

TSXV:NSCI

CA$51.4m

CNSX:SCYB

CA$8.7m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Is Aurora Spine (CVE:ASG) A Risky Investment?

Full year 2023 earnings released: US$0.02 loss per share (vs US$0.022 loss in FY 2022)

Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

Recent updates

Is Aurora Spine (CVE:ASG) A Risky Investment?

Full year 2023 earnings released: US$0.02 loss per share (vs US$0.022 loss in FY 2022)

Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.002 loss in 3Q 2022)

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System

Second quarter 2023 earnings released: US$0.01 loss per share (vs US$0.002 loss in 2Q 2022)

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.04 loss in FY 2021)

Independent Chairman exercised options to buy CA$355k worth of stock.

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Third quarter 2022 earnings released: US$0.002 loss per share (vs US$0.007 loss in 3Q 2021)

Aurora Spine Corporation to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Zip(TM) MIS Interspinous Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for Its Silo TFX MIS Sacroiliac Joint Fixation System

Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.013 loss in 2Q 2021)

Aurora Spine Corporation to Report Q2, 2022 Results on Aug 29, 2022

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Announces New FDA Indication Clearance of Lumbar Spinal Stenosis for Its ZIP™ Series of MIS Implants

Aurora Spine Corporation Receives FDA 510(K) Clearance for Its Dexa Solo-LTM Spinal Fusion System

Aurora Spine Corporation to Report Q1, 2022 Results on May 23, 2022

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Full year 2021 earnings released: US$0.04 loss per share (vs US$0.004 loss in FY 2020)

Insufficient new directors

Aurora Spine Corporation Announces Initial Implantation of the First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Receives Notice of Allowance for Patent for Spinal Implant for Motion Preservation or Fusion

Aurora Spine Corporation Completes First Anterior Cervical Discectomy and Fusion Procedures with its Proprietary APOLLOTM Anterior Cervical Plate

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Aurora Spine Corporation Announces Newly Published Paper on Need for A Bone Mineral Density-Matched Interbody Cage

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.006 profit in 3Q 2020)

Aurora Spine Corporation Will Showcase Its New FDA-Cleared DEXA-C Anterior Fusion Cages At the North American Spine Society Annual Meeting

Aurora Spine Corporation announced that it has received CAD 6.508139 million in funding

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.001 profit in 2Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Announces First Patients in Multicenter Study of ZIP® Interspinous Fixation Device

Aurora Spine Corporation Announces FDA 510(K) Clearance for DEXA-C Cervical Interbody System

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

First quarter 2021 earnings released: US$0.01 loss per share (vs US$0.011 loss in 1Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Receives Irb Approval to Commence Registration for Multicenter Study of Its Silo™ Device for Si Joint Pain

Full year 2020 earnings released

Aurora Spine Corporation Announces Launch of its SiLOTM Posterior SI Joint Fusion System

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

New 90-day high: CA$0.53

Erträge & Einnahmen